- Home
- ANTX vs NRXP Comparison
ANTX vs NRXP Comparison
Compare ANTX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- NRXP
- Stock Information
- Founded
- ANTX 2017
- NRXP 2015
- Country
- ANTX United States
- NRXP United States
- Employees
- ANTX N/A
- NRXP N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- NRXP Health Care
- Exchange
- ANTX Nasdaq
- NRXP Nasdaq
- Market Cap
- ANTX 33.2M
- NRXP 32.6M
- IPO Year
- ANTX 2022
- NRXP N/A
- Fundamental
- Price
- ANTX $1.07
- NRXP $3.21
- Analyst Decision
- ANTX Buy
- NRXP Strong Buy
- Analyst Count
- ANTX 2
- NRXP 4
- Target Price
- ANTX $2.00
- NRXP $28.50
- AVG Volume (30 Days)
- ANTX 254.6K
- NRXP 202.4K
- Earning Date
- ANTX 08-12-2025
- NRXP 08-13-2025
- Dividend Yield
- ANTX N/A
- NRXP N/A
- EPS Growth
- ANTX N/A
- NRXP N/A
- EPS
- ANTX N/A
- NRXP N/A
- Revenue
- ANTX N/A
- NRXP N/A
- Revenue This Year
- ANTX N/A
- NRXP N/A
- Revenue Next Year
- ANTX N/A
- NRXP N/A
- P/E Ratio
- ANTX N/A
- NRXP N/A
- Revenue Growth
- ANTX N/A
- NRXP N/A
- 52 Week Low
- ANTX $0.87
- NRXP $1.10
- 52 Week High
- ANTX $3.07
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- ANTX 45.67
- NRXP 51.07
- Support Level
- ANTX $1.05
- NRXP $3.12
- Resistance Level
- ANTX $1.11
- NRXP $3.53
- Average True Range (ATR)
- ANTX 0.04
- NRXP 0.18
- MACD
- ANTX 0.00
- NRXP -0.05
- Stochastic Oscillator
- ANTX 33.33
- NRXP 41.82
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.